Valo Health CEO: We Don’t Want Investors To Drive the Science
Brian Alexander feels the current system of drug development is shaped by biotech investor expectations. Valo Health is eschewing that path.
The 4 Biotech Companies on Track to IPO this Week Despite the Government Shutdown
Across all industries, the total number of companies on track to go public could make this week the most active for IPOs since 2021. Despite the partial government shutdown, there are paths biotechs can pursue to the public markets.
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
How DiME’s New Pediatric Rare Disease Project Could Make Clinical Trials Faster
The Digital Medicine Society (DiME) launched a new set of FDA-aligned digital measures to standardize how outcomes are tracked in pediatric rare disease trials. The framework aims to make trials faster and more efficient, giving researchers and drugmakers a practical roadmap for developing new therapies for children who often have no effective treatment options.
Roche Obesity Drug’s Phase 2 Results Are Competitive, But True Test May Come From Combo Studies
Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity.
Crescent Bio Expands Its Cancer Drug Combo Ambitions With New Kelun-Biotech Alliance
Crescent Biopharma gains rights to a Kelun-Biotech antibody drug conjugate it plans to test in combination with its lead cancer drug, a bispecific antibody designed to block PD-1 and VEGF. Separately, Crescent raised $185 million in a private placement to support its clinical trial plans.
Cleveland Clinic Taps Dyania Health to Speed Up Clinical Trials with AI
Cleveland Clinic is expanding its use of Dyania Health’s AI platform across the health system to speed up clinical trial recruitment. The system quickly scans patient records to identify eligible participants, aiming to give more patients access to trials and speed up development timelines for new therapies.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Carving a Path Toward Pragmatic Innovation in Clinical Trials
Prioritizing risk-based management, data science, smart automation, standards, and patient optionality are critical for the industry to keep up with market changes. The recent FDA guidance that encourages ‘pragmatic trials’ in specific scenarios is a move in the right direction.
AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma
AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile.
Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia
The ability to harness real-world insights at scale empowers life sciences companies and clinicians to develop more targeted therapies, improve patient outcomes, and drive evidence-based innovation in BPH treatment.
The AIQ Imperative: A New Competitive Paradigm for BioPharma
AIQ is not just about adopting a new technology. We’re talking about a fundamentally different way of thinking. A shift in what’s possible in clinical research, and a new standard for execution.
presented by
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Building Service Infrastructure for “Made-To-Order” Therapies
By reimagining clinical trials as the initial step in designing a service ecosystem, organizations can accelerate time to delivery and lay the groundwork for successful commercialization.
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.
Bridging Clinical Research Gaps: How Site Augmentation Enhances Trial Success
Understanding how site augmentation services could be leveraged to overcome challenges is not the responsibility of one entity. The most creative and effective solutions arise from collaboration among all stakeholders — sponsors, CROs, service providers, and research sites.
Future Trends for Clinical Trials in 2025 and Beyond
Four key predictions for the future of clinical trials, examining how these changes will revolutionize the speed, efficiency, and reliability of bringing life-saving treatments to market.
Challenges and Opportunities for Digital Innovation in Clinical Trials
The clinical trial process is complex, long, and always arduous. But the results of the drug development process can be amazing, new, safe, effective, life-changing, and life-enhancing therapies.